Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation

Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation

ObjectivesRezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus an...

Full description

Saved in:
Bibliographic Details
Main Authors: Juan Hong, Xiaohui Zeng, Wenjun Chen, Ziyuan Zhou, Yuming He, Jun Meng, Lihui Ouyang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Public Health
Subjects:
cost-effectiveness
rezvilutamide
bicalutamide
high-volume mHSPC
Markov model
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1574780/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items